Actinogen Medical Limited (ASX:ACW)

Australia flag Australia · Delayed Price · Currency is AUD
0.0420
+0.0010 (2.44%)
At close: Mar 6, 2026
35.48%
Market Cap 150.18M
Revenue (ttm) 7.36M
Net Income (ttm) -17.91M
Shares Out 3.58B
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,721,342
Average Volume 3,415,759
Open 0.0420
Previous Close 0.0410
Day's Range 0.0400 - 0.0420
52-Week Range 0.0190 - 0.0720
Beta 0.90
RSI 43.71
Earnings Date Feb 19, 2026

About Actinogen Medical

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 6
Stock Exchange Australian Securities Exchange
Ticker Symbol ACW
Full Company Profile

Financial Performance

In fiscal year 2025, Actinogen Medical's revenue was 5.49 million, a decrease of -44.73% compared to the previous year's 9.93 million. Losses were -14.73 million, 12.9% more than in 2024.

Financial Statements

News

There is no news available yet.